Rezo Therapeutics maps disease networks to develop precision medicines. Its SSD platform combines proteomics, genetics, structural biology, chemistry, and bioinformatics to build maps of molecular disease networks and identify druggable targets, with a focus on solid tumors. Unlike single-target approaches, it maps whole networks to reveal tumor-specific vulnerabilities and guide therapy development, supported by UCSF QBI origins. The goal is to translate network biology into a pipeline of targeted therapeutics through internal programs and strategic partnerships.
Company Size
11-50
Company Stage
Series A
Total Funding
$78M
Headquarters
San Francisco, California
Founded
2021
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?